Kura Oncology (KURA) EBT Margin (2025 - 2026)
Kura Oncology (KURA) posted quarterly EBT Margin of 401.45% for Q1 2026, up 401.0% year-over-year from 80.13% in Q1 2025, and up 14.0% quarter-over-quarter from 466.82% in Q4 2025.
Kura Oncology (KURA) EBT Margin (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported EBT Margin for 2 consecutive years, with 401.45% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 401.0% year-over-year to 401.45%; the TTM figure through Mar 2026 stood at 411.08% (changed N/A YoY), while the FY2025 annual figure was 412.51%, changed N/A from the prior year.
- EBT Margin advanced to 401.45% in Q1 2026 per KURA's latest filing, from 466.82% in the prior quarter.
- Across five years, EBT Margin topped out at 357.19% in Q3 2025 and bottomed at 466.82% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | -327.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -327.31% |
| Mar 31, 2026 | -401.45% |
| Dec 31, 2025 | -466.82% |
| Sep 30, 2025 | -357.19% |
| Jun 30, 2025 | -432.51% |
| Mar 31, 2025 | -405.46% |